Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Adds five years of market exclusivity on approval
On track to complete the BLA submission in the first half of 2022
Subscribe To Our Newsletter & Stay Updated
